AnaptysBio, Inc.
ANAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.11 | -0.06 | -0.09 |
| FCF Yield | -36.11% | -21.09% | -8.47% | -4.96% |
| EV / EBITDA | -6.71 | -3.90 | -7.80 | -8.59 |
| Quality | ||||
| ROIC | -26.11% | -39.45% | -19.60% | -8.92% |
| Gross Margin | 97.37% | 86.15% | 77.30% | -55.91% |
| Cash Conversion Ratio | 0.93 | 0.74 | 0.57 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 107.03% | -35.24% | -48.43% | 99.14% |
| Free Cash Flow Growth | -11.58% | -64.44% | -56.39% | -221.11% |
| Safety | ||||
| Net Debt / EBITDA | -2.66 | 0.13 | 0.49 | 8.52 |
| Interest Coverage | -2.29 | -9.09 | -5.46 | -39.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -446.39 | -575.96 | -384.84 | -1.39 |